Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

1.

TP53 Status is Associated with Thrombospondin1 Expression In vitro.

Alvarez Secord A, Bernardini MQ, Broadwater G, Grace LA, Huang Z, Baba T, Kondoh E, Sfakianos G, Havrilesky LJ, Murphy SK.

Front Oncol. 2013 Oct 29;3:269. doi: 10.3389/fonc.2013.00269. eCollection 2013.

PMID:
24195060
[PubMed]
Free PMC Article
2.

Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines.

Davidson BA, Rubatt JM, Corcoran DL, Teoh DK, Bernardini MQ, Grace LA, Soper WJ, Berchuck A, Siamakpour-Reihani S, Chen W, Owzar K, Murphy SK, Secord AA.

Front Oncol. 2014 Jun 20;4:163. doi: 10.3389/fonc.2014.00163. eCollection 2014.

PMID:
24999452
[PubMed]
Free PMC Article
3.

The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study.

Alvarez Secord A, Darcy KM, Hutson A, Huang Z, Lee PS, Jewell EL, Havrilesky LJ, Markman M, Muggia F, Murphy SK.

Gynecol Oncol. 2011 Nov;123(2):314-9. doi: 10.1016/j.ygyno.2011.08.003. Epub 2011 Sep 8.

PMID:
21903246
[PubMed - indexed for MEDLINE]
4.

TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).

Cheng LL, Itahana Y, Lei ZD, Chia NY, Wu Y, Yu Y, Zhang SL, Thike AA, Pandey A, Rozen S, Voorhoeve PM, Yu Q, Tan PH, Bay BH, Itahana K, Tan P.

Clin Cancer Res. 2012 Aug 1;18(15):4201-12. doi: 10.1158/1078-0432.CCR-12-0036. Epub 2012 Jun 6.

PMID:
22675170
[PubMed - indexed for MEDLINE]
Free Article
5.

Differential expression of angiogenesis-related genes in human gastric cancers with and those without high-frequency microsatellite instability.

Miyamoto N, Yamamoto H, Taniguchi H, Miyamoto C, Oki M, Adachi Y, Imai K, Shinomura Y.

Cancer Lett. 2007 Aug 28;254(1):42-53. Epub 2007 Mar 19.

PMID:
17374440
[PubMed - indexed for MEDLINE]
6.

Methylation and silencing of the Thrombospondin-1 promoter in human cancer.

Li Q, Ahuja N, Burger PC, Issa JP.

Oncogene. 1999 May 27;18(21):3284-9.

PMID:
10359534
[PubMed - indexed for MEDLINE]
Free Article
7.

Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status.

Sandulache VC, Skinner HD, Ow TJ, Zhang A, Xia X, Luchak JM, Wong LJ, Pickering CR, Zhou G, Myers JN.

Cancer. 2012 Feb 1;118(3):711-21. doi: 10.1002/cncr.26321. Epub 2011 Jun 30.

PMID:
21720999
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Tumor hypoxia, p53, and prognosis in cervical cancers.

Haensgen G, Krause U, Becker A, Stadler P, Lautenschlaeger C, Wohlrab W, Rath FW, Molls M, Dunst J.

Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):865-72.

PMID:
11429213
[PubMed - indexed for MEDLINE]
9.

Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.

Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih IeM, Kurman RJ.

Mod Pathol. 2011 Sep;24(9):1248-53. doi: 10.1038/modpathol.2011.85. Epub 2011 May 6.

PMID:
21552211
[PubMed - indexed for MEDLINE]
Free Article
11.

Poorer outcome in stromal HIF-2 alpha- and CA9-positive colorectal adenocarcinomas is associated with wild-type TP53 but not with BNIP3 promoter hypermethylation or apoptosis.

Cleven AH, Wouters BG, Schutte B, Spiertz AJ, van Engeland M, de Bruïne AP.

Br J Cancer. 2008 Sep 2;99(5):727-33. doi: 10.1038/sj.bjc.6604547. Epub 2008 Aug 19.

PMID:
18728663
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Mutations of TP53 induce loss of DNA methylation and amplification of the TROP1 gene.

Nasr AF, Nutini M, Palombo B, Guerra E, Alberti S.

Oncogene. 2003 Mar 20;22(11):1668-77.

PMID:
12642870
[PubMed - indexed for MEDLINE]
13.

Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.

Karamurzin Y, Leitao MM Jr, Soslow RA.

Am J Surg Pathol. 2013 Mar;37(3):356-67. doi: 10.1097/PAS.0b013e318272ff19.

PMID:
23282975
[PubMed - indexed for MEDLINE]
14.

TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.

Rechsteiner M, Zimmermann AK, Wild PJ, Caduff R, von Teichman A, Fink D, Moch H, Noske A.

Exp Mol Pathol. 2013 Oct;95(2):235-41. doi: 10.1016/j.yexmp.2013.08.004. Epub 2013 Aug 18.

PMID:
23965232
[PubMed - indexed for MEDLINE]
15.

Profile of p53 expression in bladder and oral tumours. Effects of in vitro manipulations of p53 on the behaviour of established human tumour cell lines.

Nouri AM, Cannell H, Dagini B, Dabare AA, Habib N, Fowler CG.

Eur J Cancer. 2000 Sep;36(14):1853-62.

PMID:
10974634
[PubMed - indexed for MEDLINE]
16.

TP53 promoter methylation in human gliomas.

Amatya VJ, Naumann U, Weller M, Ohgaki H.

Acta Neuropathol. 2005 Aug;110(2):178-84. Epub 2005 Jul 16.

PMID:
16025287
[PubMed - indexed for MEDLINE]
17.

The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation.

Sernbo S, Gustavsson E, Brennan DJ, Gallagher WM, Rexhepaj E, Rydnert F, Jirström K, Borrebaeck CA, Ek S.

BMC Cancer. 2011 Sep 24;11:405. doi: 10.1186/1471-2407-11-405.

PMID:
21943380
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers.

Sundaram P, Hultine S, Smith LM, Dews M, Fox JL, Biyashev D, Schelter JM, Huang Q, Cleary MA, Volpert OV, Thomas-Tikhonenko A.

Cancer Res. 2011 Dec 15;71(24):7490-501. doi: 10.1158/0008-5472.CAN-11-1124. Epub 2011 Oct 25.

PMID:
22028325
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer.

Sanchez-Carbayo M, Socci ND, Kirchoff T, Erill N, Offit K, Bochner BH, Cordon-Cardo C.

Clin Cancer Res. 2007 Jun 1;13(11):3215-20.

PMID:
17545525
[PubMed - indexed for MEDLINE]
Free Article
20.

O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course.

Watanabe T, Katayama Y, Komine C, Yoshino A, Ogino A, Ohta T, Fukushima T.

Int J Cancer. 2005 Feb 10;113(4):581-7.

PMID:
15455376
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk